An epidemiologist hired by a dying woman who contends that Johnson & Johnson and Colgate-Palmolive's talcum products contained cancer-causing asbestos told a California jury on Wednesday it "makes sense" that asbestos exposure in the woman's teens would cause her mesothelioma decades later.
Monsanto asked a California appeals court Tuesday to reverse a $78.5 million verdict awarded to a school groundskeeper who claimed Roundup weedkiller caused his lymphoma in the first landmark trial over the herbicide’s alleged cancer risks.
The Federal Trade Commission said Wednesday that it has sued Surescripts in D.C. federal court over allegations that the company uses contract terms and other tactics to illegally maintain its monopoly over electronic prescription services.
One of the five former Insys Therapeutics Inc. executives on trial for conspiring to bribe doctors to prescribe an opioid spray to patients who did not need it is asking the court to let her await her verdict from home as the jury enters its 11th day of deliberation.
A Philadelphia jury hammered a Johnson & Johnson unit with $120 million in damages Wednesday after agreeing that a negligently designed pelvic mesh implant left a woman all but incontinent and suffering from chronic pain that prevented her from having sex.
An investor sued Boston Scientific on Wednesday over the 7.7% drop in share price that followed the U.S. Food and Drug Administration's decision last week to pull the company's surgical mesh products from the U.S. market.
A food and health watchdog group has urged the U.S. Food and Drug Administration to crack down on certain dietary supplements that have been touted as help for smokers trying to quit but haven't undergone FDA scrutiny for effectiveness or safety.
A shareholder suit filed Tuesday in Boston federal court accuses London-based gene therapy developer Nightstar Therapeutics of leaving out key information in a regulatory filing about Biogen's plan to buy the company for $877 million, and asks a judge to delay a vote on the deal.
Biotech and pharmaceutical industry groups urged the full Federal Circuit on Monday to rethink a February ruling that nixed Athena Diagnostics' patent on an autoimmune disease testing method, saying the ruling threatens U.S. leadership in the diagnostic industry and other biotech sectors.
An attorney for Colgate-Palmolive told a California jury Tuesday that its former talc product Cashmere Bouquet was sourced from asbestos-free mines and had nothing to do with a 61-year-old woman's mesothelioma, which she claims was caused by Colgate and Johnson & Johnson talc products.
The U.S. Department of Justice’s first felony charges accusing a drug distributor of fueling the opioid crisis involve familiar allegations of reckless painkiller sales that until now have been punished with civil penalties. But the accusations are also backed up by direct accounts of C-suite complicity, one of several factors that likely tipped the case into criminal waters.
Amazon notched a partial win Tuesday in a suit alleging a man was gravely injured by a faulty walker he purchased through the site, after a South Carolina federal court tossed two claims against the e-commerce giant and left two others hanging by a thread.
Purchasers of Allergan's ulcerative colitis drug lodged a last-ditch effort for class certification in their antitrust suit, asking a Massachusetts federal judge Monday to reconsider denying them a chance to rework their bid after an appellate court rejected an earlier iteration.
Big companies and other organizations across a variety of industries are boosting their ethics and compliance efforts, particularly in internal investigations, according to a new report from KPMG LLP.
Synergy Pharmaceuticals Inc. received court approval Tuesday to wind down in Chapter 11 under a bankruptcy plan that provides creditors with recoveries from a $195 million sale of the company's drug treatments to Bausch Health Cos. Inc., overcoming challenges from the federal government's bankruptcy case watchdog.
Bausch Health Cos. Inc. on Tuesday said that Johnson & Johnson has agreed to cover the costs of litigation over a "Shower to Shower" talc powder product that Bausch acquired in 2012.
Cancer-focused biotechnology firm Poseida Therapeutics Inc. has decided to put plans for an initial public offering on hold, with the Cooley LLP-guided company instead picking up $142 million in a funding round led by pharmaceutical giant Novartis.
The former chief financial officer of Aveo Pharmaceuticals asked a Massachusetts federal judge on Monday to erase the verdict against him for civil securities violations, saying it was based on a misreading of the law.
A California federal judge has thrown out pet medicine distributors' renewed challenge to the merger of two rivals, calling it too much like an earlier version that she said failed to make an antitrust case.
Prosecutors sought to preserve the conviction of Martin Shkreli's former attorney Evan Greebel on Monday, telling the Second Circuit that his claim that jury instructions used the wrong definition of a lawyer's "duty" was an attempt to draw a "fine-to-nonexistent line" that made no difference at his trial.
In a recent Law360 guest article, the author applauded the disappearance of jury trials as an inefficient, costly mechanism, but in doing so he overlooked the greater value of jury trials for our justice system, says Stephen Susman, executive director of the Civil Jury Project at NYU School of Law.
During the past 15 years, three widely read articles bolstered by starstruck media have promulgated the incorrect perception — sorely in need of revision — that the U.S. Supreme Court bar is limited to a handful of elite lawyers, says Lawrence Ebner of Capital Appellate Advocacy.
On April 4, the U.S. Department of Justice announced three settlements of False Claims Act cases, offering a glimpse into the ways the DOJ believes pharmaceutical companies have used charitable copay foundations to cover copays of government health program beneficiaries, circumvent anti-kickback laws and artificially bolster high drug prices, say attorneys with Skadden.
While Federal Circuit decisions have created a patenting barrier for diagnostics and personalized medicine claims, the U.S. Patent and Trademark Office's revised patent subject matter eligibility guidance may allow for these patents to make a comeback, say attorneys with Morris Manning.
A critical component of any virtual law team assembled for mass tort litigation is a dedicated "law team," which tackles the legal strategy and drafts the many necessary pleadings, motions and other submissions, say attorneys at Pepper Hamilton and Faegre.
Recently unsealed indictments from the U.S. Department of Justice make clear that telemedicine will continue to be an enforcement focus at a time when telemedicine is expanding, and should remind providers to focus on compliance obligations, say Edgar Bueno and Matthew Wilmot of Morris Manning.
In patenting innovations involving artificial intelligence, there is uncertainty on issues like inventorship, adequacy of disclosure, assessment of nonobviousness, and patent eligibility. The field of biotechnology once faced similar challenges, say Enrica Bruno and Brian Cash of Steinfl & Bruno.
As the cannabis industry continues to grow, it will need more legal professionals to help navigate the turbulent business landscape, but lawyers should understand the industry's unique limitations and characteristics before diving in, says Sabas Carrillo of consulting firm Adnant.
A recent Law360 article reported on federal judges bemoaning jury trials' nationwide decline, but these laments are unfounded as jury trials have been replaced by better alternatives, says J.B. Heaton of J.B. Heaton Research.
Recent Federal Trade Commission blog posts suggest potentially increased interest in the genetic testing arena, and the vague recommendations they offer may give the FTC broad latitude from an enforcement perspective, say attorneys at Moses & Singer.